What to Know When Prostate Cancer Spreads to Bones

Bone is the most common destination for prostate cancer cells that leave the prostate, and up to three-quarters of men with advanced disease eventually develop bone metastases.¹ Learning that cancer has reached the bone understandably feels like a turning point, and it is one, but the picture is more nuanced than many people expect. Treatments have multiplied over the past decade, the biology of prostate cancer in bone is genuinely unusual compared to other cancers, and quality of life can often be preserved for years with the right combination of therapies.

Why Prostate Cancer Targets Bone

Not every cancer has the same appetite for bone, and prostate cancer’s preference is striking. The anatomy helps explain it. A network of veins called the vertebral venous plexus connects the pelvic region directly to the spine, ribs, and pelvis without passing through the lungs first. Animal studies confirmed decades ago that tumor cells travelling through this low-pressure vein network preferentially seed the lumbar spine and nearby bones.² That is why spinal vertebrae, pelvic bones, and ribs are the sites that show up most often on scans.

Once prostate cancer cells arrive in bone, though, they do something unusual. Most cancers that spread to bone, like breast or lung cancer, primarily eat away at the existing bone in a destructive process. Prostate cancer does the opposite: it triggers abnormal new bone formation. The tumor secretes signaling proteins, including bone morphogenetic proteins and endothelin-1, that stimulate the bone-forming cells (osteoblasts) to lay down dense, disordered bone tissue.³ Researchers have also found that prostate cancer cells can actually convert the lining cells of nearby blood vessels into osteoblasts, further accelerating the abnormal bone buildup.⁴

The new bone is not healthy bone. It is structurally chaotic, weaker than the bone it replaces, and paradoxically prone to fracture despite appearing denser on scans. And the process is not purely bone-building: prostate cancer cells also produce a protein called RANKL that activates bone-destroying cells (osteoclasts), so both formation and destruction happen simultaneously.³ This cycle of creation and destruction is self-reinforcing. Broken-down bone releases growth factors that feed the cancer, which in turn drives more bone turnover. Understanding this vicious cycle matters because it is the direct target of several key treatments.

What Bone Metastases Actually Do to the Skeleton

The complications that bone metastases cause, often grouped under the term “skeletal-related events,” are the reason this diagnosis demands active management. They include pathological fractures, spinal cord compression, and severe bone pain.¹ Each of these can significantly erode quality of life. Research looking at patient-reported outcomes has found meaningful declines in physical, functional, and emotional well-being after fractures and radiation treatment for bone pain.⁵

Pain is the most common problem and often the first signal that cancer has reached bone. It tends to be a deep, constant ache that worsens at night or with activity, though it can also present as sharp, sudden pain when a weakened bone gives way under normal stress. A vertebral compression fracture can happen from something as simple as bending forward or coughing hard. These events are not just painful; they can cascade. A fracture leads to immobility, which leads to muscle loss, which raises the risk of another fracture.

Spinal Cord Compression as an Emergency

Among the skeletal complications, spinal cord compression deserves special attention because it is a genuine oncologic emergency. When tumor growth in or near a vertebra presses on the spinal cord, the resulting damage to nerve function can progress from back pain to weakness to paralysis within days or even hours. A study of men who underwent surgery for metastatic spinal cord compression found that outcomes depended heavily on timing: patients who had been unable to walk for fewer than 48 hours before surgery were far more likely to regain the ability to walk than those whose paralysis had lasted longer.⁶ The message for patients and caregivers is straightforward: new or rapidly worsening back pain, leg weakness, numbness, or difficulty controlling bladder or bowel function should prompt same-day contact with the care team.

The question of whether routine screening spinal MRIs in men with known spinal metastases could prevent these emergencies was tested in a large randomized trial. It found that the rate of clinical spinal cord compression was low in both screened and unscreened groups, and routine screening MRI did not reduce the problem enough to justify its use.⁷ In practical terms, this means watchful awareness of new neurological symptoms matters more than scheduled imaging in most men with spinal metastases.

How Bone Metastases Are Found and Tracked

Traditionally, bone metastases have been detected using conventional bone scans, which track where a radioactive tracer accumulates in areas of active bone turnover. These scans are widely available and relatively inexpensive, but they lack fine detail. Newer imaging using PSMA PET/CT, which targets a protein found on prostate cancer cells, has generated enthusiasm for its precision. A phase 2 trial comparing the two approaches in men progressing on hormone therapy found that PSMA PET/CT and bone scan plus CT had the same per-patient detection rate for bone lesions. PSMA PET/CT did pick up more individual lesions per patient in about a quarter of cases.⁸ So PSMA PET/CT can offer a more detailed picture of disease burden, though the conventional bone scan remains a reasonable starting tool.

Beyond imaging, blood and urine markers of bone turnover can help track what is happening between scans. Markers that reflect bone breakdown, especially one called N-telopeptide, have been shown to predict the risk of fractures, disease progression, and death in men with bone metastases. Elevated levels of bone formation markers like alkaline phosphatase are also linked to worse outcomes.⁹ In men treated with bone-protecting drugs, serial measurements of these markers have been able to distinguish between those whose bone disease was progressing and those whose disease was stable, sometimes more clearly than PSA alone.¹⁰ These markers are not used as standalone diagnostic tools, but they add another data point to the overall picture.

Bone-Protecting Medications

Two drugs are the backbone of bone protection in metastatic prostate cancer: zoledronic acid, an intravenous bisphosphonate given roughly every four weeks, and denosumab, a subcutaneous injection that blocks the RANKL protein mentioned earlier. Both work by slowing down the bone-destroying side of the cycle, reducing fracture risk and delaying other skeletal complications.

In a head-to-head trial involving over 1,900 men with castration-resistant prostate cancer and bone metastases, denosumab delayed the first skeletal-related event by about three and a half months longer than zoledronic acid, with a median time of roughly 21 months versus 17 months.¹¹ Denosumab also delayed the onset of subsequent skeletal events. That statistical edge led many oncologists to favor denosumab, especially for patients with castration-resistant disease. However, the choice between the two is not purely about efficacy; their side-effect profiles differ, and cost and insurance coverage play a role in real-world decision-making.

Combining bone-protective treatment with newer hormonal therapies like abiraterone or enzalutamide appears to provide added benefit. A study of men who started bone-targeted therapy alongside one of these hormonal agents as first-line treatment found a roughly 40 percent lower risk of skeletal-related events compared with those who either never received bone-targeted therapy or started it later.¹²

Jaw Osteonecrosis and Other Risks of Bone-Protecting Drugs

A side effect that deserves its own discussion is medication-related osteonecrosis of the jaw, where a section of the jawbone loses its blood supply and begins to die. This is uncommon but serious, and it becomes more likely with longer use of bone-protective agents. Multiple studies in prostate cancer patients have identified denosumab as carrying a higher risk than zoledronic acid. One analysis found the hazard ratio for jaw osteonecrosis with denosumab was roughly four to five times higher compared with zoledronic acid.¹³ Other risk factors include having six or more bone metastases, concurrent chemotherapy, diabetes, and longer duration of treatment.¹⁴ ¹⁵

Spacing out doses to intervals longer than one month was associated with a substantially lower risk.¹³ Practically, this means a thorough dental exam before starting bone-protective therapy is essential, and ongoing dental hygiene during treatment is more than a footnote. Invasive dental procedures while on these drugs should be coordinated with your oncology team.

Radiation for Bone Pain

When a bone metastasis causes persistent pain that is not adequately controlled by medications, palliative radiation is one of the most effective interventions available. It works by shrinking the tumor and reducing the inflammatory signaling that drives bone pain. For decades, conventional external beam radiation delivered in a handful of sessions has been the standard. More recently, stereotactic body radiotherapy, which delivers a high, precisely focused dose in fewer treatments, has gained ground.

A systematic review and meta-analysis comparing the two found that overall pain response rates were similar, but a higher proportion of patients treated with stereotactic radiation achieved complete pain relief.¹⁶ Prospective trials have confirmed that stereotactic radiation to painful bone sites is effective and well-tolerated.¹⁷ The practical takeaway is that if bone pain persists despite other treatments, radiation is a well-proven option worth discussing. Many men experience meaningful relief within a week or two of treatment.

Radium-223 and Radioligand Therapies

Radium-223 dichloride is a unique treatment because it combines radiation and bone biology. As a calcium-mimicking alpha emitter, it naturally incorporates into areas of active bone formation, which is exactly where prostate cancer bone metastases concentrate. It then delivers short-range, high-energy radiation that kills nearby cancer cells while largely sparing surrounding healthy tissue. In the landmark ALSYMPCA trial, radium-223 extended overall survival by about three and a half months compared with placebo in men with castration-resistant prostate cancer and symptomatic bone metastases, with a median survival of roughly 15 months versus 11 months.¹⁸ This remains one of the few bone-targeted therapies shown to improve survival rather than just delay complications. Safety data have confirmed that standard dosing is well-tolerated for palliative treatment of bone pain.¹⁹

A newer approach is lutetium-177 PSMA radioligand therapy, which targets the PSMA protein on prostate cancer cells wherever they are in the body, including bone. In patients with diffuse bone metastases, roughly half achieved a 50 percent or greater drop in PSA, and those responders lived longer than non-responders. About 43 percent reported meaningful pain relief.²⁰ Even in patients with an extremely heavy bone disease burden, described as a “superscan” pattern where essentially the entire skeleton lights up on imaging, lutetium-177 PSMA therapy still produced PSA responses and manageable side effects, though overall survival in this subgroup was shorter.²¹

Calcium Problems You Might Not Expect

Most people associate cancer with high calcium levels, but prostate cancer bone metastases often do the opposite. Because the tumor drives aggressive new bone formation, calcium is pulled from the bloodstream and deposited into the skeleton. Roughly three-quarters of cases of low calcium related to cancer metastases have been attributed to prostate cancer specifically.²² This is the reverse of what happens in most other advanced cancers, and it can catch clinicians and patients off guard.

Low calcium carries its own risks: muscle cramps, tingling in the fingers and around the mouth, irregular heartbeat, and in severe cases, seizures. A study of nearly 200 men with hormone-refractory prostate cancer and bone metastases found that those with low calcium had heavier bone disease, higher markers of bone turnover, and lower hemoglobin, all of which point to more advanced illness.²³ Adding bone-protective drugs like denosumab, which further suppress bone breakdown, can worsen hypocalcemia. Calcium and vitamin D supplementation alongside these medications is standard practice, and regular monitoring of calcium levels is important.

When Cancer Infiltrates the Bone Marrow

Bone metastases and bone marrow involvement are related but not identical. In some men, cancer cells infiltrate the marrow cavity itself so heavily that the marrow can no longer produce blood cells effectively. This is rare but dangerous. A real-world cohort study found that at the time of bone marrow metastasis diagnosis, over 90 percent of patients had anemia, over 80 percent had low platelet counts, and nearly half had low white blood cell counts. Survival in this group was extremely limited.²⁴ This scenario typically signals that the cancer has become very aggressive, and treatment options are narrowed by the very blood count problems the marrow failure creates, since chemotherapy and some other therapies require adequate blood cell levels to be given safely.

Surgery for Skeletal Metastases

Surgery is not the primary treatment for bone metastases, but it has a specific role: stabilizing bones that have fractured or are about to fracture, and decompressing the spinal cord when it is being squeezed by tumor growth. A large series of over 300 prostate cancer patients who underwent surgery for skeletal metastases found a median survival of about six months after the operation, with a one-year survival rate of roughly 29 percent.²⁵ The reoperation rate was about 9 percent, most often for infection or bleeding complications. These numbers reflect that surgery in this setting is typically palliative, aimed at maintaining function and reducing pain rather than curing the disease. For men with spinal cord compression, the speed of surgical intervention is a major predictor of whether they regain or keep the ability to walk.

Exercise With Bone Metastases

A common concern is whether physical activity is safe when cancer is in the bones. There is a reasonable fear that exercise could cause a fracture at a weakened site. The evidence is reassuring. A systematic review of exercise programs for individuals with bone metastases found that serious adverse events related to exercise were extremely rare, at about 0.5 percent across studies, and none of the serious events were related to the bone metastases themselves.²⁶ A trial specifically in prostate cancer patients with bone metastases found that supervised resistance exercise was well-tolerated, with high attendance and compliance rates and zero skeletal complications during sessions.²⁷

The key qualifier is “supervised.” Most of the successful programs involved exercise professionals who could modify movements based on where the metastases were and how much bone was involved. Working out independently with heavy weights or high-impact activities is a different proposition from a tailored program with professional guidance. If you have bone metastases and want to stay active, an exercise physiologist or physical therapist experienced in oncology rehabilitation can design a safe plan. Maintaining muscle strength and mobility is directly relevant to preventing falls and fractures, so doing nothing carries its own risk.

Managing Pain and Symptoms Over Time

Men with bone metastatic prostate cancer can live for years after the diagnosis, which means symptom management is a long game, not a one-time fix.²⁸ Pain is typically managed with a layered approach: analgesic medications ranging from anti-inflammatories to opioids, bone-protective agents to slow the underlying bone destruction, palliative radiation for focal pain, and radionuclide therapy for more widespread bone disease. Each layer can be adjusted over time as the disease changes.

Beyond pain, fatigue is nearly universal, and its causes are often stacked: the cancer itself, the hormonal treatments that suppress testosterone, anemia from bone marrow involvement or treatment effects, and the deconditioning that comes with reduced activity. Supportive care interventions, including exercise programs, psychosocial support, and symptom-focused nursing care, have shown positive trends, though published research on these interventions in advanced prostate cancer specifically remains limited.²⁹ Asking your care team about palliative care early, rather than waiting until the end of treatment options, is one of the most useful things you can do. Palliative care is not the same as hospice; it is specialist-level symptom management that runs alongside active cancer treatment and can meaningfully improve day-to-day life.